MAPK8 and plasma cell myeloma: BCMA is a TNF receptor in the NF-κB, MAPK/ERK, p38, and JNK/Elk-1 signaling pathways that promotes cells’ growth, proliferation, and survival, as well as maintenance of an immunosuppressive tumor microenvironment in both benign and neoplastic myeloma and other lymphoproliferative malignancies [7].